News
The most recent news and industry headlines are presented in this section. Our dedicated team closely observes the pharmaceutical industry and keeps you informed of the most recent developments around the Europe.
PolyPid Announces Exclusive Licensing Agreement with ADVANZ PHARMA for the Commercialization of D-PLEX₁₀₀ in Europe
Thursday, August 04, 2022PolyPid Ltd a latestage biopharma company aiming to improve surgical outcomes today announced that it has entered into an exclusive licensing agreement with ADVANZ PHARMA Corp a UKbased global specialty and hospital pharmaceutical company for the com...
Kiniksa Pharmaceuticals Announces Global License Agreement with Genentech for Vixarelimab
Thursday, August 04, 2022Kiniksa Pharmaceuticals Ltd a biopharmaceutical company with a portfolio of assets designed to modulate immunological pathways across a spectrum of diseases today announced a global license agreement with Roche and Genentech a member of the Roche Gro...
InterVenn Biosciences Announces Start of Enrollment in Colonoscopy Study
Wednesday, August 03, 2022InterVenn Biosciences a clinical technology company leveraging glycoproteomics to transform the future of healthcare today announced the start of enrollment in its prospective cohort study for early detection of colorectal cancer and adenomas This co...
Adalvo Acquires Its First Branded Product, Onsolis®
Wednesday, August 03, 2022The global pharmaceutical company Adalvo today announced the acquisition of its first branded product Onsolis after concluding a deal with a reputable US based specialty pharmaceutical Company that originally owned the product The brand is an opioid...
Ipsen to acquire exclusive rights to investigational ERK inhibitor as part of its existing research collaboration with AGV Discovery
Tuesday, August 02, 2022Ipsen and AGV Discovery today announced that Ipsen has exercised its option to acquire exclusive worldwide rights to an investigational ERK inhibitor discovered by AGV Discovery The decision follows the successful achievement of a key developmental m...
Celyad Oncology Announces FDA Lifts Clinical Hold of CYAD-101-002 Phase 1b Trial
Tuesday, August 02, 2022Celyad Oncology SA a clinicalstage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell CAR T therapies for cancer today announced that the US Food and Drug Administration FDA has lifted the clinical hold...
ImmunityBio Announces FDA Acceptance of Biologics License Application for N-803 in BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer Carcinoma In Situ
Friday, July 29, 2022The FDA has accepted ImmunityBio Incs Biologics License Application BLA for review The BLA pertains to an antibody cytokine fusion protein intended for the treatment of BCGunresponsive nonmuscleinvasive bladder cancer carcinoma in situ CIS with or wi...
SOTIO Doses First Patient in AURELIO-04 Phase 2 Trial of SOT101 in Combination with KEYTRUDA® (pembrolizumab)
Wednesday, July 27, 2022SOTIO Biotech a clinicalstage immunooncology company owned by PPF Group has announced that it has exercised its first exclusive option with LegoChem Biosciences for the antibodydrug conjugate ADC SOT The ADC is currently undergoing preclinical studie...
Rockley Photonics Announces Strategic Partnership with Leading Contract Research Organization
Wednesday, July 27, 2022Rockley Photonics Holdings Limited a global leader in photonicsbased health monitoring and communications solutions today announced a new partnership with a top ten global contract research organization CRO that provides fullservice clinical developm...
DiaCarta Receives CE-IVD Mark for Its SARS CoV-2 Flu A/B Combo Test
Thursday, July 21, 2022DiaCarta Inc precision molecular diagnostics company CEIVD mark QuantiVirus SARSCoV Flu AB Test RealTime PCR test qualitative detection nucleic acid SARSCoV
